This is an open-label SPECT/CT (single photon emission computed tomography / computed
tomography) study to investigate the safety and diagnostic performance of 99mTc-3PRGD2 in
evaluation of lung cancer patients. A single dose of nearly 11.1 MBq/kg body weight of
99mTc-3PRGD2 ( ≤ 20 µg 3PRGD2) will be intravenously injected into the patients in suspicion
of lung cancer. Visual and semiquantitative method will be used to assess the whole-body
planar and thoracic SPECT/CT images. Any adverse events will be collected from the patients.